topotecan has been researched along with nifurtimox in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forman, E; Greenlaw, C; Kalkunte, S; McCarten, K; Saulnier Sholler, GL | 1 |
| Ashikaga, T; Bergendahl, GM; Bingham, PM; Brard, L; Ferguson, WS; Heath, BW; Higgins, TJ; Homans, AC; Kamen, BA; Lenox, SR; Saulnier Sholler, GL; Singh, AP; Slavik, MA | 1 |
| Bruchelt, G; Cabanillas Stanchi, KM; Handgretinger, R; Holzer, U | 1 |
1 trial(s) available for topotecan and nifurtimox
| Article | Year |
|---|---|
A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Maximum Tolerated Dose; Neuroblastoma; Nifurtimox; Recurrence; Topotecan; Treatment Outcome | 2011 |
2 other study(ies) available for topotecan and nifurtimox
| Article | Year |
|---|---|
Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chagas Disease; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Neuroblastoma; Nifurtimox; Recurrence; Remission Induction; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.
Topics: Aerobiosis; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Glycolysis; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nifurtimox; Nuclear Proteins; Oncogene Proteins; Oxidative Stress; Proto-Oncogene Mas; Reactive Oxygen Species; Topotecan | 2015 |